OPKO Health, Inc. (NASDAQ:OPK) Receives $2.75 Average Target Price from Analysts

Key Points

• OPKO Health, Inc. has received a consensus recommendation of "Moderate Buy" from six research firms, with an average 12-month price target of $2.75.
• Despite these positive ratings, OPKO Health reported a significant earnings miss for the last quarter, posting a loss of ($0.19) EPS compared to analysts' expectations of ($0.12).
• CEO Phillip Frost recently acquired 675,000 shares of the company's stock, indicating strong insider confidence despite ongoing challenges.

Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $2.75.

Several brokerages have weighed in on OPK. Wall Street Zen lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. LADENBURG THALM/SH SH raised shares of OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. Finally, Zacks Research raised shares of OPKO Health from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th.

Insider Activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $891,000.00. Following the acquisition, the chief executive officer owned 214,676,448 shares of the company's stock, valued at approximately $283,372,911.36. This represents a 0.32% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 49.69% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Oak Thistle LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at about $26,000. GM Advisory Group LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at about $33,000. Cerity Partners LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at about $36,000. Pallas Capital Advisors LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at about $43,000. Finally, Voleon Capital Management LP acquired a new position in shares of OPKO Health in the 1st quarter valued at about $45,000. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Trading Down 2.8%

Shares of OPK stock traded down $0.04 during mid-day trading on Friday, reaching $1.38. The company's stock had a trading volume of 1,663,914 shares, compared to its average volume of 2,347,663. The company's 50 day simple moving average is $1.34 and its 200-day simple moving average is $1.45. OPKO Health has a 12-month low of $1.11 and a 12-month high of $2.04. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $1.10 billion, a PE ratio of -5.52 and a beta of 1.40.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The business had revenue of $156.80 million during the quarter, compared to analysts' expectations of $165.74 million. During the same period in the prior year, the business posted ($0.01) EPS. The business's revenue was down 13.9% on a year-over-year basis. On average, research analysts predict that OPKO Health will post -0.25 EPS for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.